| Abstrakt: |
Asthma is frequently comorbid with chronic rhinosinusitis. First line pharmacologic intervention for asthma includes combination inhaled corticosteroids (ICS) with a long-acting β-agonist (LABA), preferably formoterol. While short-acting-β-agonists (SABA) have historically been used as lone rescues, studies show that this approach can lead to more asthma-related exacerbations and greater mortality. Similarly, oral corticosteroids (OCS) should be used sparingly due to their significant adverse effect profile. Non-pharmacological interventions for asthma include counseling on modifiable risk factors, such as smoking, physical activity, occupational exposures, and healthy diets. Simultaneous treatment of CRS can lead to improvements in asthma control, medication usage, and quality of life measures. Management of patients with unified airway disease should incorporate a multidisciplinary team comprised of otolaryngologists and asthma specialists. |
